Influence of BRAF mutations and RAC1b/RAC1 mRNA ratio or protein expression on outcome in patients with metastatic Colorectal Cancer (mCRC) treated with first-line chemotherapy

被引：0
|
作者：
Cuatrecasas, M. [1 ]
Alonso-Espinaco, V. [1 ]
Jares, P. [1 ]
Horndler, C. [1 ]
Castells, A. [1 ]
Lozano, J. J. [1 ]
Maurel, J. [1 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
来源：
VIRCHOWS ARCHIV | 2012年 / 461卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV)
    Ning, Yen
    Zhang, Wu
    Yang, Dongyun
    Stintzing, Sebastian
    Sunakawa, Yu
    Stremitzer, Stefan
    Sablo, Ana
    Yamauchi, Shinichi
    Matsusaka, Satoshi
    Zoratto, Federica
    Loupakis, Fotios
    El-Khoueiry, Rita Elie
    Barzi, Afsaneh
    El-Khoueiry, Anthony B.
    Kahn, Michael
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/ FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
    Bruera, Gemma
    Malapelle, Umberto
    Pepe, Francesco
    Pisapia, Pasquale
    Dal Mas, Antonella
    Calvisi, Giuseppe
    Troncone, Giancarlo
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Influence of KRAS exon 2 mutation variants as well as NRAS-and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.
    Modest, Dominik Paul
    Ricard, Ingrid
    Heinemann, Volker
    Hegewisch-Becker, Susanna
    Schmiegel, Wolff H.
    Porschen, Rainer
    Stintzing, Sebastian
    Graeven, Ullrich
    Arnold, Dirk
    Von Weikersthal, Ludwig Fischer
    Giessen-Jung, Clemens
    Stahler, Arndt
    Schmoll, Hans-Joachim
    Jung, Andreas
    Kirchner, Thomas
    Tannapfel, Andrea
    Reinacher-Schick, Anke C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study
    Valladares-Ayerbes, M.
    Garcia-Alfonso, P.
    Munoz Luengo, J.
    Pimentel Caceres, P.
    Vieitez, J. M.
    Cruz-Hernandez, J. J.
    Llanos, M.
    Garcia Giron, C.
    Cirera, L.
    Lloansi Vila, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 202 - 202
  • [45] Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
    Stahler, Arndt
    Stintzing, Sebastian
    Urbischek, Manuela
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Kumbrink, Joerg
    Heinemann, Volker
    Kirchner, Thomas
    Jung, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Influence of mRNA expression of epiregulin (EREG) and of amphiregulin (AREG) and RAS mutationson outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
    Stahler, Arndt
    Heinemann, Volker
    Giessen, Clemens Albrecht
    Crispin, Alexander
    Schalhorn, Alexander
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Stauch, Martina
    Qietzsch, Detief
    Neumann, Jens
    Kirchner, Thomas
    Jung, Andreas
    Modest, Dominik Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.
    Bruera, Gemma
    Pepe, Francesco
    Malapelle, Umberto
    Pisapia, Pasquale
    Dal Mas, Antonella
    Marchetti, Paolo
    Calvisi, Giuseppe
    Troncone, Giancarlo
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy
    Saridaki, Z.
    Tzardi, M.
    Papadatos-Patsos, D.
    Kampouraki, E.
    Zois, E.
    Stathopoulos, E.
    Georgoulias, V.
    Mavroudis, D.
    Souglakos, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 91 - 92
  • [49] Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
    Papadaki, C.
    Tsaroucha, E.
    Kaklamanis, L.
    Lagoudaki, E.
    Trypaki, M.
    Tryfonidis, K.
    Mavroudis, D.
    Stathopoulos, E.
    Georgoulias, V.
    Souglakos, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (02) : 316 - 323
  • [50] Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
    C Papadaki
    E Tsaroucha
    L Kaklamanis
    E Lagoudaki
    M Trypaki
    K Tryfonidis
    D Mavroudis
    E Stathopoulos
    V Georgoulias
    J Souglakos
    British Journal of Cancer, 2011, 104 : 316 - 323
12345